I have done that is recent patients, yes. I am doing it because "on paper" I see better PFS and better ORR, of course in addition to the non-inferiority when compared to sorafenib in the randomized trial that is now published. However, I am building experience with respect to tolerance in my parti...

The REFLECT trial, which demonstrated non-inferiority between lenvatinib and sorafenib in terms of survival, demonstrated an improved response rate with lenvatinib.  However, this study enrolled a select patient population, with less than 50% of their liver involved and with good liver function...

To play devil's advocate, I will say no. While numerically the PFS and ORR may appear higher than Sorafenib, the study was not powered for superiority, thus, one can only truly state that Lenvatinib is not inferior to Sorafenib, not equal. In regards to ORR observed with Lenvatinib, I do not know ...